Publication Date
1-1-2023
Journal
The Journal of Cancer
DOI
10.1097/PPO.0000000000000637
PMID
36693154
PMCID
PMC9881841
PubMedCentral® Posted Date
1-1-2024
PubMedCentral® Full Text Version
Post-print
Published Open-Access
yes
Keywords
Humans, T-Lymphocytes, Neoplasms, Immunotherapy, Adoptive, Immunotherapy, Cell- and Tissue-Based Therapy, Cellular Immunotherapy, Chimeric antigen receptor (CAR)- T cell therapy, lymphoid malignancies, multiple myeloma, adoptive cell therapy, off-the-shelf cell therapy
Abstract
Cellular immunotherapy of cancer in the form of chimeric antigen receptor-modified T-cell therapy has become a standard treatment for lymphoid and more recently plasma cell malignancies. Although their successes in these cancers represent a breakthrough for adoptive cell therapy, there are several challenges to their continued growth in the field of cancer medicine. In this review, we discuss the progress made thus far toward achieving "off-the-shelf" accessibility of cell therapies that has the potential to greatly offset the costs associated with the current practice of making patient-specific products. We also review the innovations under investigation that attempt to make cellular therapy applicable to solid tumors as well.
Included in
Biological Phenomena, Cell Phenomena, and Immunity Commons, Immunotherapy Commons, Medical Cell Biology Commons, Neoplasms Commons, Oncology Commons